nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP3A5—Paclitaxel—ovarian cancer	0.0887	0.154	CbGbCtD
Nevirapine—CYP2D6—Vinorelbine—ovarian cancer	0.0775	0.134	CbGbCtD
Nevirapine—CYP3A4—Topotecan—ovarian cancer	0.0699	0.121	CbGbCtD
Nevirapine—CYP3A5—Docetaxel—ovarian cancer	0.0642	0.111	CbGbCtD
Nevirapine—CYP2B6—Doxorubicin—ovarian cancer	0.0607	0.105	CbGbCtD
Nevirapine—CYP2C9—Paclitaxel—ovarian cancer	0.0595	0.103	CbGbCtD
Nevirapine—CYP3A4—Vinorelbine—ovarian cancer	0.0493	0.0853	CbGbCtD
Nevirapine—CYP3A4—Paclitaxel—ovarian cancer	0.0346	0.0599	CbGbCtD
Nevirapine—CYP2D6—Doxorubicin—ovarian cancer	0.0293	0.0508	CbGbCtD
Nevirapine—CYP3A4—Docetaxel—ovarian cancer	0.025	0.0433	CbGbCtD
Nevirapine—CYP3A4—Doxorubicin—ovarian cancer	0.0187	0.0323	CbGbCtD
Nevirapine—Anorexia—Vinorelbine—ovarian cancer	0.000774	0.00183	CcSEcCtD
Nevirapine—Skin exfoliation—Doxorubicin—ovarian cancer	0.000773	0.00183	CcSEcCtD
Nevirapine—Asthenia—Chlorambucil—ovarian cancer	0.000765	0.00181	CcSEcCtD
Nevirapine—Neutropenia—Docetaxel—ovarian cancer	0.000762	0.0018	CcSEcCtD
Nevirapine—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000756	0.00179	CcSEcCtD
Nevirapine—Pruritus—Chlorambucil—ovarian cancer	0.000755	0.00179	CcSEcCtD
Nevirapine—Urticaria—Topotecan—ovarian cancer	0.000754	0.00179	CcSEcCtD
Nevirapine—Abdominal pain—Topotecan—ovarian cancer	0.000751	0.00178	CcSEcCtD
Nevirapine—Body temperature increased—Topotecan—ovarian cancer	0.000751	0.00178	CcSEcCtD
Nevirapine—Lymphadenopathy—Epirubicin—ovarian cancer	0.000745	0.00176	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00074	0.00175	CcSEcCtD
Nevirapine—Urticaria—Melphalan—ovarian cancer	0.000739	0.00175	CcSEcCtD
Nevirapine—Rash maculo-papular—Doxorubicin—ovarian cancer	0.000736	0.00174	CcSEcCtD
Nevirapine—Mouth ulceration—Doxorubicin—ovarian cancer	0.000732	0.00173	CcSEcCtD
Nevirapine—Diarrhoea—Chlorambucil—ovarian cancer	0.00073	0.00173	CcSEcCtD
Nevirapine—Paraesthesia—Vinorelbine—ovarian cancer	0.000729	0.00173	CcSEcCtD
Nevirapine—Erythema multiforme—Paclitaxel—ovarian cancer	0.000727	0.00172	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.00072	0.0017	CcSEcCtD
Nevirapine—Renal failure—Docetaxel—ovarian cancer	0.000714	0.00169	CcSEcCtD
Nevirapine—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000712	0.00168	CcSEcCtD
Nevirapine—Jaundice—Docetaxel—ovarian cancer	0.000708	0.00167	CcSEcCtD
Nevirapine—Hepatic failure—Epirubicin—ovarian cancer	0.000707	0.00167	CcSEcCtD
Nevirapine—Decreased appetite—Vinorelbine—ovarian cancer	0.000706	0.00167	CcSEcCtD
Nevirapine—Conjunctivitis—Docetaxel—ovarian cancer	0.000706	0.00167	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000701	0.00166	CcSEcCtD
Nevirapine—Fatigue—Vinorelbine—ovarian cancer	0.0007	0.00166	CcSEcCtD
Nevirapine—Hypersensitivity—Topotecan—ovarian cancer	0.0007	0.00166	CcSEcCtD
Nevirapine—Pain—Vinorelbine—ovarian cancer	0.000695	0.00164	CcSEcCtD
Nevirapine—Immune system disorder—Paclitaxel—ovarian cancer	0.000695	0.00164	CcSEcCtD
Nevirapine—Lymphadenopathy—Doxorubicin—ovarian cancer	0.000689	0.00163	CcSEcCtD
Nevirapine—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000687	0.00163	CcSEcCtD
Nevirapine—Hypersensitivity—Melphalan—ovarian cancer	0.000685	0.00162	CcSEcCtD
Nevirapine—Asthenia—Topotecan—ovarian cancer	0.000681	0.00161	CcSEcCtD
Nevirapine—Vomiting—Chlorambucil—ovarian cancer	0.000678	0.0016	CcSEcCtD
Nevirapine—Agranulocytosis—Docetaxel—ovarian cancer	0.000678	0.0016	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Epirubicin—ovarian cancer	0.000674	0.00159	CcSEcCtD
Nevirapine—Pruritus—Topotecan—ovarian cancer	0.000672	0.00159	CcSEcCtD
Nevirapine—Erythema—Paclitaxel—ovarian cancer	0.000669	0.00158	CcSEcCtD
Nevirapine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000669	0.00158	CcSEcCtD
Nevirapine—Asthenia—Melphalan—ovarian cancer	0.000667	0.00158	CcSEcCtD
Nevirapine—Dermatitis bullous—Epirubicin—ovarian cancer	0.000665	0.00157	CcSEcCtD
Nevirapine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000664	0.00157	CcSEcCtD
Nevirapine—Pruritus—Melphalan—ovarian cancer	0.000658	0.00156	CcSEcCtD
Nevirapine—Hepatic failure—Doxorubicin—ovarian cancer	0.000654	0.00155	CcSEcCtD
Nevirapine—Hepatitis—Docetaxel—ovarian cancer	0.000652	0.00154	CcSEcCtD
Nevirapine—Diarrhoea—Topotecan—ovarian cancer	0.00065	0.00154	CcSEcCtD
Nevirapine—Urticaria—Vinorelbine—ovarian cancer	0.000645	0.00153	CcSEcCtD
Nevirapine—Body temperature increased—Vinorelbine—ovarian cancer	0.000642	0.00152	CcSEcCtD
Nevirapine—Abdominal pain—Vinorelbine—ovarian cancer	0.000642	0.00152	CcSEcCtD
Nevirapine—Connective tissue disorder—Docetaxel—ovarian cancer	0.000641	0.00152	CcSEcCtD
Nevirapine—Diarrhoea—Melphalan—ovarian cancer	0.000636	0.00151	CcSEcCtD
Nevirapine—Nausea—Chlorambucil—ovarian cancer	0.000634	0.0015	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Doxorubicin—ovarian cancer	0.000623	0.00147	CcSEcCtD
Nevirapine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000621	0.00147	CcSEcCtD
Nevirapine—Anaemia—Paclitaxel—ovarian cancer	0.000619	0.00146	CcSEcCtD
Nevirapine—Erythema multiforme—Docetaxel—ovarian cancer	0.000616	0.00146	CcSEcCtD
Nevirapine—Dermatitis bullous—Doxorubicin—ovarian cancer	0.000615	0.00146	CcSEcCtD
Nevirapine—Face oedema—Epirubicin—ovarian cancer	0.000614	0.00145	CcSEcCtD
Nevirapine—Angioedema—Paclitaxel—ovarian cancer	0.000612	0.00145	CcSEcCtD
Nevirapine—Vomiting—Topotecan—ovarian cancer	0.000604	0.00143	CcSEcCtD
Nevirapine—Malaise—Paclitaxel—ovarian cancer	0.000604	0.00143	CcSEcCtD
Nevirapine—Rash—Topotecan—ovarian cancer	0.000599	0.00142	CcSEcCtD
Nevirapine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000598	0.00142	CcSEcCtD
Nevirapine—Dermatitis—Topotecan—ovarian cancer	0.000598	0.00142	CcSEcCtD
Nevirapine—Headache—Topotecan—ovarian cancer	0.000595	0.00141	CcSEcCtD
Nevirapine—Vomiting—Melphalan—ovarian cancer	0.000591	0.0014	CcSEcCtD
Nevirapine—Immune system disorder—Docetaxel—ovarian cancer	0.000589	0.00139	CcSEcCtD
Nevirapine—Liver function test abnormal—Epirubicin—ovarian cancer	0.000587	0.00139	CcSEcCtD
Nevirapine—Rash—Melphalan—ovarian cancer	0.000586	0.00139	CcSEcCtD
Nevirapine—Dermatitis—Melphalan—ovarian cancer	0.000586	0.00139	CcSEcCtD
Nevirapine—Asthenia—Vinorelbine—ovarian cancer	0.000583	0.00138	CcSEcCtD
Nevirapine—Pruritus—Vinorelbine—ovarian cancer	0.000575	0.00136	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000572	0.00135	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000572	0.00135	CcSEcCtD
Nevirapine—Arthralgia—Paclitaxel—ovarian cancer	0.00057	0.00135	CcSEcCtD
Nevirapine—Myalgia—Paclitaxel—ovarian cancer	0.00057	0.00135	CcSEcCtD
Nevirapine—Face oedema—Doxorubicin—ovarian cancer	0.000568	0.00134	CcSEcCtD
Nevirapine—Erythema—Docetaxel—ovarian cancer	0.000567	0.00134	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000566	0.00134	CcSEcCtD
Nevirapine—Nausea—Topotecan—ovarian cancer	0.000564	0.00133	CcSEcCtD
Nevirapine—Discomfort—Paclitaxel—ovarian cancer	0.000563	0.00133	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000561	0.00133	CcSEcCtD
Nevirapine—Diarrhoea—Vinorelbine—ovarian cancer	0.000556	0.00132	CcSEcCtD
Nevirapine—Nausea—Melphalan—ovarian cancer	0.000552	0.00131	CcSEcCtD
Nevirapine—Oedema—Paclitaxel—ovarian cancer	0.000546	0.00129	CcSEcCtD
Nevirapine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000546	0.00129	CcSEcCtD
Nevirapine—Eosinophilia—Epirubicin—ovarian cancer	0.000544	0.00129	CcSEcCtD
Nevirapine—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000543	0.00128	CcSEcCtD
Nevirapine—Pancreatitis—Epirubicin—ovarian cancer	0.000539	0.00127	CcSEcCtD
Nevirapine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000536	0.00127	CcSEcCtD
Nevirapine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000535	0.00127	CcSEcCtD
Nevirapine—Skin disorder—Paclitaxel—ovarian cancer	0.000531	0.00126	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.00053	0.00125	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.00053	0.00125	CcSEcCtD
Nevirapine—Anaemia—Docetaxel—ovarian cancer	0.000524	0.00124	CcSEcCtD
Nevirapine—Anorexia—Paclitaxel—ovarian cancer	0.000521	0.00123	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000519	0.00123	CcSEcCtD
Nevirapine—Vomiting—Vinorelbine—ovarian cancer	0.000516	0.00122	CcSEcCtD
Nevirapine—Neutropenia—Epirubicin—ovarian cancer	0.000514	0.00122	CcSEcCtD
Nevirapine—Rash—Vinorelbine—ovarian cancer	0.000512	0.00121	CcSEcCtD
Nevirapine—Dermatitis—Vinorelbine—ovarian cancer	0.000512	0.00121	CcSEcCtD
Nevirapine—Headache—Vinorelbine—ovarian cancer	0.000509	0.0012	CcSEcCtD
Nevirapine—Eosinophilia—Doxorubicin—ovarian cancer	0.000503	0.00119	CcSEcCtD
Nevirapine—Pancreatitis—Doxorubicin—ovarian cancer	0.000498	0.00118	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000498	0.00118	CcSEcCtD
Nevirapine—Hyperglycaemia—Epirubicin—ovarian cancer	0.000496	0.00117	CcSEcCtD
Nevirapine—Paraesthesia—Paclitaxel—ovarian cancer	0.000491	0.00116	CcSEcCtD
Nevirapine—Somnolence—Paclitaxel—ovarian cancer	0.000486	0.00115	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000486	0.00115	CcSEcCtD
Nevirapine—Arthralgia—Docetaxel—ovarian cancer	0.000483	0.00114	CcSEcCtD
Nevirapine—Myalgia—Docetaxel—ovarian cancer	0.000483	0.00114	CcSEcCtD
Nevirapine—Nausea—Vinorelbine—ovarian cancer	0.000483	0.00114	CcSEcCtD
Nevirapine—Renal failure—Epirubicin—ovarian cancer	0.000481	0.00114	CcSEcCtD
Nevirapine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.00048	0.00114	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00048	0.00114	CcSEcCtD
Nevirapine—Jaundice—Epirubicin—ovarian cancer	0.000477	0.00113	CcSEcCtD
Nevirapine—Conjunctivitis—Epirubicin—ovarian cancer	0.000476	0.00113	CcSEcCtD
Nevirapine—Neutropenia—Doxorubicin—ovarian cancer	0.000475	0.00112	CcSEcCtD
Nevirapine—Decreased appetite—Paclitaxel—ovarian cancer	0.000475	0.00112	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000472	0.00112	CcSEcCtD
Nevirapine—Fatigue—Paclitaxel—ovarian cancer	0.000471	0.00111	CcSEcCtD
Nevirapine—Pain—Paclitaxel—ovarian cancer	0.000467	0.00111	CcSEcCtD
Nevirapine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000463	0.0011	CcSEcCtD
Nevirapine—Oedema—Docetaxel—ovarian cancer	0.000463	0.0011	CcSEcCtD
Nevirapine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000463	0.0011	CcSEcCtD
Nevirapine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000458	0.00108	CcSEcCtD
Nevirapine—Agranulocytosis—Epirubicin—ovarian cancer	0.000457	0.00108	CcSEcCtD
Nevirapine—Nervous system disorder—Docetaxel—ovarian cancer	0.000454	0.00107	CcSEcCtD
Nevirapine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000453	0.00107	CcSEcCtD
Nevirapine—Feeling abnormal—Paclitaxel—ovarian cancer	0.00045	0.00107	CcSEcCtD
Nevirapine—Skin disorder—Docetaxel—ovarian cancer	0.00045	0.00106	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000449	0.00106	CcSEcCtD
Nevirapine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000447	0.00106	CcSEcCtD
Nevirapine—Renal failure—Doxorubicin—ovarian cancer	0.000445	0.00105	CcSEcCtD
Nevirapine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000444	0.00105	CcSEcCtD
Nevirapine—Jaundice—Doxorubicin—ovarian cancer	0.000442	0.00105	CcSEcCtD
Nevirapine—Anorexia—Docetaxel—ovarian cancer	0.000441	0.00104	CcSEcCtD
Nevirapine—Conjunctivitis—Doxorubicin—ovarian cancer	0.00044	0.00104	CcSEcCtD
Nevirapine—Hepatitis—Epirubicin—ovarian cancer	0.00044	0.00104	CcSEcCtD
Nevirapine—Urticaria—Paclitaxel—ovarian cancer	0.000434	0.00103	CcSEcCtD
Nevirapine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000432	0.00102	CcSEcCtD
Nevirapine—Body temperature increased—Paclitaxel—ovarian cancer	0.000432	0.00102	CcSEcCtD
Nevirapine—Abdominal pain—Paclitaxel—ovarian cancer	0.000432	0.00102	CcSEcCtD
Nevirapine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000429	0.00101	CcSEcCtD
Nevirapine—Agranulocytosis—Doxorubicin—ovarian cancer	0.000423	0.001	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000422	0.000998	CcSEcCtD
Nevirapine—Paraesthesia—Docetaxel—ovarian cancer	0.000416	0.000984	CcSEcCtD
Nevirapine—Erythema multiforme—Epirubicin—ovarian cancer	0.000416	0.000984	CcSEcCtD
Nevirapine—Somnolence—Docetaxel—ovarian cancer	0.000412	0.000974	CcSEcCtD
Nevirapine—Hepatitis—Doxorubicin—ovarian cancer	0.000407	0.000963	CcSEcCtD
Nevirapine—Decreased appetite—Docetaxel—ovarian cancer	0.000403	0.000953	CcSEcCtD
Nevirapine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000403	0.000953	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.0004	0.000946	CcSEcCtD
Nevirapine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.0004	0.000946	CcSEcCtD
Nevirapine—Fatigue—Docetaxel—ovarian cancer	0.000399	0.000945	CcSEcCtD
Nevirapine—Immune system disorder—Epirubicin—ovarian cancer	0.000397	0.00094	CcSEcCtD
Nevirapine—Pain—Docetaxel—ovarian cancer	0.000396	0.000937	CcSEcCtD
Nevirapine—Asthenia—Paclitaxel—ovarian cancer	0.000392	0.000928	CcSEcCtD
Nevirapine—Pruritus—Paclitaxel—ovarian cancer	0.000387	0.000915	CcSEcCtD
Nevirapine—Erythema multiforme—Doxorubicin—ovarian cancer	0.000385	0.00091	CcSEcCtD
Nevirapine—Erythema—Epirubicin—ovarian cancer	0.000383	0.000906	CcSEcCtD
Nevirapine—Feeling abnormal—Docetaxel—ovarian cancer	0.000382	0.000903	CcSEcCtD
Nevirapine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000379	0.000896	CcSEcCtD
Nevirapine—Diarrhoea—Paclitaxel—ovarian cancer	0.000374	0.000885	CcSEcCtD
Nevirapine—Immune system disorder—Doxorubicin—ovarian cancer	0.000367	0.00087	CcSEcCtD
Nevirapine—Body temperature increased—Docetaxel—ovarian cancer	0.000366	0.000866	CcSEcCtD
Nevirapine—Abdominal pain—Docetaxel—ovarian cancer	0.000366	0.000866	CcSEcCtD
Nevirapine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000355	0.00084	CcSEcCtD
Nevirapine—Erythema—Doxorubicin—ovarian cancer	0.000354	0.000838	CcSEcCtD
Nevirapine—Anaemia—Epirubicin—ovarian cancer	0.000354	0.000837	CcSEcCtD
Nevirapine—Vomiting—Paclitaxel—ovarian cancer	0.000347	0.000822	CcSEcCtD
Nevirapine—Malaise—Epirubicin—ovarian cancer	0.000345	0.000817	CcSEcCtD
Nevirapine—Rash—Paclitaxel—ovarian cancer	0.000344	0.000815	CcSEcCtD
Nevirapine—Dermatitis—Paclitaxel—ovarian cancer	0.000344	0.000814	CcSEcCtD
Nevirapine—Headache—Paclitaxel—ovarian cancer	0.000342	0.00081	CcSEcCtD
Nevirapine—Hypersensitivity—Docetaxel—ovarian cancer	0.000341	0.000807	CcSEcCtD
Nevirapine—Asthenia—Docetaxel—ovarian cancer	0.000332	0.000786	CcSEcCtD
Nevirapine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000329	0.000778	CcSEcCtD
Nevirapine—Pruritus—Docetaxel—ovarian cancer	0.000328	0.000775	CcSEcCtD
Nevirapine—Anaemia—Doxorubicin—ovarian cancer	0.000327	0.000775	CcSEcCtD
Nevirapine—Myalgia—Epirubicin—ovarian cancer	0.000326	0.000771	CcSEcCtD
Nevirapine—Arthralgia—Epirubicin—ovarian cancer	0.000326	0.000771	CcSEcCtD
Nevirapine—Nausea—Paclitaxel—ovarian cancer	0.000325	0.000768	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000324	0.000766	CcSEcCtD
Nevirapine—Discomfort—Epirubicin—ovarian cancer	0.000322	0.000762	CcSEcCtD
Nevirapine—Malaise—Doxorubicin—ovarian cancer	0.000319	0.000756	CcSEcCtD
Nevirapine—Diarrhoea—Docetaxel—ovarian cancer	0.000317	0.00075	CcSEcCtD
Nevirapine—Oedema—Epirubicin—ovarian cancer	0.000312	0.000739	CcSEcCtD
Nevirapine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000312	0.000739	CcSEcCtD
Nevirapine—Nervous system disorder—Epirubicin—ovarian cancer	0.000306	0.000725	CcSEcCtD
Nevirapine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000306	0.000724	CcSEcCtD
Nevirapine—Skin disorder—Epirubicin—ovarian cancer	0.000303	0.000718	CcSEcCtD
Nevirapine—Arthralgia—Doxorubicin—ovarian cancer	0.000301	0.000713	CcSEcCtD
Nevirapine—Myalgia—Doxorubicin—ovarian cancer	0.000301	0.000713	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000299	0.000709	CcSEcCtD
Nevirapine—Discomfort—Doxorubicin—ovarian cancer	0.000298	0.000705	CcSEcCtD
Nevirapine—Anorexia—Epirubicin—ovarian cancer	0.000298	0.000705	CcSEcCtD
Nevirapine—Vomiting—Docetaxel—ovarian cancer	0.000294	0.000697	CcSEcCtD
Nevirapine—Rash—Docetaxel—ovarian cancer	0.000292	0.000691	CcSEcCtD
Nevirapine—Dermatitis—Docetaxel—ovarian cancer	0.000292	0.00069	CcSEcCtD
Nevirapine—Headache—Docetaxel—ovarian cancer	0.00029	0.000687	CcSEcCtD
Nevirapine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000289	0.000684	CcSEcCtD
Nevirapine—Oedema—Doxorubicin—ovarian cancer	0.000289	0.000684	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000285	0.000673	CcSEcCtD
Nevirapine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000283	0.000671	CcSEcCtD
Nevirapine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000283	0.00067	CcSEcCtD
Nevirapine—Skin disorder—Doxorubicin—ovarian cancer	0.000281	0.000664	CcSEcCtD
Nevirapine—Paraesthesia—Epirubicin—ovarian cancer	0.00028	0.000664	CcSEcCtD
Nevirapine—Somnolence—Epirubicin—ovarian cancer	0.000278	0.000657	CcSEcCtD
Nevirapine—Anorexia—Doxorubicin—ovarian cancer	0.000276	0.000652	CcSEcCtD
Nevirapine—Nausea—Docetaxel—ovarian cancer	0.000275	0.000651	CcSEcCtD
Nevirapine—Decreased appetite—Epirubicin—ovarian cancer	0.000272	0.000643	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00027	0.000638	CcSEcCtD
Nevirapine—Fatigue—Epirubicin—ovarian cancer	0.000269	0.000637	CcSEcCtD
Nevirapine—Pain—Epirubicin—ovarian cancer	0.000267	0.000632	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000263	0.000623	CcSEcCtD
Nevirapine—Paraesthesia—Doxorubicin—ovarian cancer	0.00026	0.000614	CcSEcCtD
Nevirapine—Feeling abnormal—Epirubicin—ovarian cancer	0.000257	0.000609	CcSEcCtD
Nevirapine—Somnolence—Doxorubicin—ovarian cancer	0.000257	0.000608	CcSEcCtD
Nevirapine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000255	0.000604	CcSEcCtD
Nevirapine—Decreased appetite—Doxorubicin—ovarian cancer	0.000251	0.000595	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00025	0.00059	CcSEcCtD
Nevirapine—Fatigue—Doxorubicin—ovarian cancer	0.000249	0.00059	CcSEcCtD
Nevirapine—Urticaria—Epirubicin—ovarian cancer	0.000248	0.000587	CcSEcCtD
Nevirapine—Pain—Doxorubicin—ovarian cancer	0.000247	0.000585	CcSEcCtD
Nevirapine—Abdominal pain—Epirubicin—ovarian cancer	0.000247	0.000584	CcSEcCtD
Nevirapine—Body temperature increased—Epirubicin—ovarian cancer	0.000247	0.000584	CcSEcCtD
Nevirapine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000238	0.000564	CcSEcCtD
Nevirapine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000236	0.000559	CcSEcCtD
Nevirapine—Hypersensitivity—Epirubicin—ovarian cancer	0.00023	0.000545	CcSEcCtD
Nevirapine—Urticaria—Doxorubicin—ovarian cancer	0.00023	0.000543	CcSEcCtD
Nevirapine—Abdominal pain—Doxorubicin—ovarian cancer	0.000228	0.000541	CcSEcCtD
Nevirapine—Body temperature increased—Doxorubicin—ovarian cancer	0.000228	0.000541	CcSEcCtD
Nevirapine—Asthenia—Epirubicin—ovarian cancer	0.000224	0.00053	CcSEcCtD
Nevirapine—Pruritus—Epirubicin—ovarian cancer	0.000221	0.000523	CcSEcCtD
Nevirapine—Diarrhoea—Epirubicin—ovarian cancer	0.000214	0.000506	CcSEcCtD
Nevirapine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000213	0.000504	CcSEcCtD
Nevirapine—Asthenia—Doxorubicin—ovarian cancer	0.000207	0.000491	CcSEcCtD
Nevirapine—Pruritus—Doxorubicin—ovarian cancer	0.000204	0.000484	CcSEcCtD
Nevirapine—Vomiting—Epirubicin—ovarian cancer	0.000199	0.00047	CcSEcCtD
Nevirapine—Diarrhoea—Doxorubicin—ovarian cancer	0.000198	0.000468	CcSEcCtD
Nevirapine—Rash—Epirubicin—ovarian cancer	0.000197	0.000466	CcSEcCtD
Nevirapine—Dermatitis—Epirubicin—ovarian cancer	0.000197	0.000466	CcSEcCtD
Nevirapine—Headache—Epirubicin—ovarian cancer	0.000196	0.000463	CcSEcCtD
Nevirapine—Nausea—Epirubicin—ovarian cancer	0.000186	0.000439	CcSEcCtD
Nevirapine—Vomiting—Doxorubicin—ovarian cancer	0.000184	0.000435	CcSEcCtD
Nevirapine—Rash—Doxorubicin—ovarian cancer	0.000182	0.000431	CcSEcCtD
Nevirapine—Dermatitis—Doxorubicin—ovarian cancer	0.000182	0.000431	CcSEcCtD
Nevirapine—Headache—Doxorubicin—ovarian cancer	0.000181	0.000428	CcSEcCtD
Nevirapine—Nausea—Doxorubicin—ovarian cancer	0.000172	0.000406	CcSEcCtD
